A305 only reviewed oncology orphans thereby resulting in inconsistent access. Alternative funding mechanisms sometimes provide a temporary reimbursement fix in the UK. Ex-factory pricing varied by country both at launch and over time. CONCLUSIONS: Significant differences exist between the number of orphan drug approvals and time to access in the US vs. EU. The US is notably faster than the EU5 and Germany is notably faster than other EU5 countries. For pricing, the US is not always the high price country. Furthermore, there appears to be an inverse relationship between size of the indicated patient population and reimbursed price.
OBJECTIVES: To explore use of electronic medical records (EMR) for identifying drivers of all-cause healthcare resource utilization and factors associated with increased resource use in patients with fibromyalgia (FM) . METHODS: This retrospective analysis used structured de-identified EMR data from the Humedica database including demographics, clinical characteristics, healthcare resource utilization, and prescriptions. Adults (≥ 18 years) with FM were identified based on ≥ 2 ICD-9 codes for FM (729.1) ≥ 30 days apart between January 1, 2008 and December 31, 2012, and were required to have ≥ 12 months continuous enrollment pre-and post-index; the first FM diagnosis was the index event. Multivariate analysis using generalized linear models evaluated how demographic and clinical characteristics relate to 12-month post-index resource utilization. RESULTS: Patients were predominantly female (81.4%), Caucasian (87.7%), with a mean±SD age of 54.4±14.8 years. Primary drivers of resource utilization were "medication orders" and "physician office visits," used by 91.6% and 87.5% of patients, respectively, with 12-month post-index means of 21±21.5 drug orders/patient and 15.1±18.1 office visits/patient, the latter accounting for 73.3% of all healthcare visits. Opioids were the most common prescription medication, 44.3% of patients. The chance of being a high healthcare resource utilizer was significantly increased (p< 0.001) 1.26-fold among African-Americans relative to Caucasians and for patients with specific comorbid conditions ranging from 1.06-fold (musculoskeletal pain and depression/bipolar disorder) to 1.21-fold (congestive heart failure). Similarly, factors significantly (p< 0.001) associated with increased number of medications ordered included being female (1.23-fold) and the presence of conditions such as sleep disorders (1.08-fold), depression/bipolar disorder (1.07-fold), and anxiety (1.06-fold). CONCLUSIONS: Physician office visits and pharmacotherapy were drivers of all-cause healthcare utilization; opioids were the most commonly prescribed medication class. Comorbid conditions were key factors associated with high resource use. EMR can be a useful tool for identifying and potentially managing FM patients with high healthcare resource utilization.
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Sugar-SweeteneD beverageS conSumPtion anD Price SenSitivitY among brazilian aDultS: imPlicationS for obeSitY PolicieS
Cardoso L. B. Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil OBJECTIVES: In this context, the challenge of this essay is to estimate the price elasticity for soda and fruit drink in Brazil and the price effects on weight outcomes and obesity prevalence. METHODS: The elasticity was measured through a two-part model (TPM) estimated for all sample and different subgroups. The empirical model explains the quantities of SSB demanded as function of its prices and other variables. Considering the estimated elasticity, we converted the reduction on consumption into weight transforming the consumption elasticity from grams to kilocalories and then we applied a frequently used rule, which considers that a reduction of 3,500 calories induces a 0,450 kg loss in body weight, everything else remaining equal. RESULTS: Overall, the results display a smaller prevalence and lower consumption with higher prices. The TPM model predicts a reduction of 348.3g in weekly soda consumption and 4.5g of fruit drink to each one Real increased price. For all sample estimates, price elasticity is -0.61 for soda and -1.32 for fruit drinks, suggesting that a 20% increase in price was associated with a decline of soda and fruit drink in weekly consumption by 12.2% and 26.4%, respectively. This evidence shows a higher sensitivity to price changes for juice drinks than for soda, in spite of the higher consumption of soda. TConsidering that weight reductions, the prevalence of overweight among adults could decline from 48.13 to 47.75 percent and obesity prevalence could be reduced from 18.77 to 18.5 percent in one year. CONCLUSIONS: Our main findings suggest that tax policy might be an effective tool to reduce the soda and juice drink consumption and body weight. We also identified that subgroups who consume higher amounts of SSB are relatively more price sensitive and in these cases pricing policies have an expressive potential in reducing SSB consumption and body weight. OBJECTIVES: In 2006, the American College of Medical Genetics (ACMG) recommended expanding NBS, relying largely on scoring from a stakeholder survey on 19 attributes of 84 rare conditions. Points were scored according to mean answers from the responders. Sums of scores resulted in 3 different entry points into an algorithm (EPA) that determined ACMG final screening recommendations. This research examines one of the survey questions about condition incidence and compares the ACMG use of surveyed opinions versus the actual facts that they also report. METHODS: The report indicated each condition's mean scores for survey questions. The incidence question scored 0-100 points. Very rare conditions ing BT alone (P< 0.001); patients receiving non-PSO concomitant medications were 19% -32% more likely to stay on their BT (p< 0.001) than those not receiving; and patients who switched BT were 2.35x more likely to stop BT within 24 months versus non-switchers (p< 0.001). Using a cost model, patients who switched BT had higher average annual costs of $4,355 and $3,679 in private and public plans respectively compared to those who didn't switch (P< 0.001). CONCLUSIONS: 68% of PSO patients on BT either switch or stop therapy, indicating there remains an unmet need for new treatment options. In addition, switching is associated with significantly higher therapy costs. With better understanding of predictors for retention, patient support programs can be designed to address the specific needs of at-risk groups.
PSY75 comPariSon of ultra orPHan anD cancer Drug Pricing in tHe uS anD tHe uk
Kumar S. 1 , Aggarwal S. 2 , Topaloglu H. 2 1 GLOBAL ACCESS Monitor, Bethesda, MD, USA, 2 NOVEL Health Strategies, Chevy Chase, MD, USA OBJECTIVES: Both ultra orphan and cancer drugs are premium priced therapies with high annual per patient costs. The local legislation and reimbursement mechanisms have had significant impact on pricing trends for these therapies. The objectives of this analysis were to compare the price differential for ultra orphan and cancer drugs in the US and the UK, and understand the impact of local reimbursement mechanisms. METHODS: A set of 22 drugs (10 ultra orphan and 12 cancer drugs) was selected based on their availability in the US and the UK. The 2014 AWP, WAC and net prices were obtained for all 22 drugs. All UK prices were converted to USD. Primary discussions with ex-payer and policy experts were conducted to understand the basis and implication of the price differentials. RESULTS: For ten selected ultra orphan drugs, the median WAC price premium for the US compared to the UK net price was 10%. For 12 selected cancer drugs the median WAC price premium for the US compared to the UK net price was 106% (based on AWP the premiums were 29% and 149%, respectively). Eight out of 10 ultra orphan and 12 out of 12 cancer drugs were higher priced in the US compared to the UK. Primary discussions with experts suggest the role of legislation for coverage of cancer drugs in the US and special coverage of rare disease products in the UK and reimbursement mechanisms (use of cost effectiveness driven HTAs in the UK and the use of co-pay in the US) as primary drivers of high price differential for cancer drugs versus ultra orphan therapies. CONCLUSIONS: The local reimbursement mechanisms are major drivers of price differential for ultra orphan and cancer drugs in the US and the UK. OBJECTIVES: Pharmaceutical manufacturers can apply to the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for orphan drug status for pharmaceuticals that treat rare medical conditions. This study compares the policies and processes that influence orphan drug designation in the US and the EU and examines the approval data to explain any differences and/or trends in decision making. METHODS: We conducted a quantitative analysis on the publicly available data on orphan drug approvals released by the FDA and EMA. By looking at the numbers of drugs approved each year, the drugs submitted and approved for orphan indications, and their relevant disease areas we were able to identify any trends and dissimilarities in the organizations final approval decisions. Following this, we performed qualitative research with a focused literature search of the Medline database and relevant websites, to explore the differences in policies and processes between the organizations that may have led to conflicting decisions. RESULTS: There were significant differences in the processes, policies and requirements for orphan drugs. The FDA consistently approved more orphan drugs each year during 2002-2014 (when comparison data were available). However, the numbers of products accepted are converging (e.g. in 2005, the EMA approved approximately 81% fewer orphan drugs; by 2013, this gap was 36%). Some differences in decisions were identified, largely due to different evidence requirements. CONCLUSIONS: The likelihood of a drug gaining orphan drug status in either the US or the EU is dependent on a number of different factors. If the trends persist, it is likely that the organizations will designate a similar number of products as orphan drugs each year, although the approved products may differ. These may affect which organization manufacturers choose to submit applications to first. OBJECTIVES: To examine pricing, reimbursement and market access of orphan drugs approved by EMA and FDA between January 2009 and December 2013. METHODS: Analyzed the orphan drugs approved by both EMA and FDA between Jan 2009 and Dec 2013, by country (US & EU5) regarding; time to market, benefit evaluations, pricing and reimbursement differences, as well as any similarities or differences by size of population. RESULTS: In the time frame, 102 orphan drugs were approved in the US vs. just 31 by the EMA. Of those, only 13 orphan drugs were approved by both agencies. For these 13 drugs, approval took an average of 66 weeks from filing with the EMA and 45 weeks with the FDA. Average US time to launch from approval was 9 weeks (only 2 weeks if one outlier is removed). In the EU, all 13 drugs were available and reimbursed on the German market in an average of 16 weeks while only 5 had completed P&R in Spain in an average of 97 weeks. Early access to reimbursement via the ATU program in France and L648 program in Italy was sometimes pursued. In the UK, SMC recommendations for orphan drugs were often negative, and NICE
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